| Trial ID: | L0510 |
| Source ID: | IRCT20161210031316N2
|
| Associated Drug: |
Losartan
|
| Title: |
Therapeutic effects of losartan in nonalcoholic steatohepatitis
|
| Acronym: |
--
|
| Status: |
Not Recruiting
|
| Study Results: |
No Results Available
|
| Results: |
--
|
| Conditions: |
NASH. <br>Nonalcoholic steatohepatitis (NASH);K75.81
|
| Interventions: |
Intervention 1: Control group: Placebo for 6 month. Intervention 2: Intervention group 1: Losartan (abidi: lostar) 25 mg daily for 6 month.
|
| Outcome Measures: |
Serum creatinin. Timepoint: Measurement of serum creatinine at baseline (before intervention) and 7 days and 1.3.6 months after initiation of losartan administration. Method of measurement: by Laboratory.;Serum potasium. Timepoint: Serum potassium measurements at the beginning of the study (before intervention) and 7 days and 1.3.6 months after the start of losartan administration. Method of measurement: by Laboratory.;Serum Alkaline phosphatase. Timepoint: Measurement of serum alkaline phosphatase at baseline (before intervention) and 3.6 months after initiation of losartan administration. Method of measurement: by Laboratory.;Serum Alanine aminotransferase. Timepoint: Measurement of serum alanine aminotransferase at baseline (before intervention) and 3.6 months after initiation of losartan administration. Method of measurement: by Laboratory.;Serum Aspartate aminotransferase. Timepoint: Measurement of serum aspartate aminotransferase at baseline (before intervention) and 3.6 months after initiation of losartan administration. Method of measurement: by Laboratory.;Blood pressure. Timepoint: Blood pressure measurement at the beginning of the study (before the intervention) and 1,2,3,4,5,6 months after the start of losartan administration. Method of measurement: Barometer.;Body Mass Index. Timepoint: Measuring the body mass index at the beginning of the study (before the intervention) and 3.6 months after starting the administration of losartan. Method of measurement: Meter , Balance.;Liver ultrasound indices. Timepoint: Measurement of liver ultrasonography at the beginning of the study (before the intervention) and 3.6 months after the start of administration of losartan. Method of measurement: Sonography.nan
|
| Sponsor/Collaborators: |
Arak University of Medical Sciences
|
| Gender: |
All
|
| Age: |
18 yearsno limit
|
| Phases: |
Phase 3
|
| Enrollment: |
42
|
| Study Type: |
interventional
|
| Study Designs: |
Randomization: Randomized, Blinding: Single blinded, Placebo: Used, Assignment: Parallel, Purpose: Treatment, Randomization description: In a simple random method, using a flip the coin, they enter one of the groups or control, Blinding description: For b
|
| Start Date: |
13/02/2018
|
| Completion Date: |
--
|
| Results First Posted: |
--
|
| Last Update Posted: |
26 March 2018
|
| Locations: |
Iran (Islamic Republic of)
|
| URL: |
http://en.irct.ir/trial/24665
|
